加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$22.40
−US$0.19 · -0.84%
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
常规交易时段
US$22.40
−US$0.19 · -0.84%
盘中时间采用ET。市场数据可能有所延迟。
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
日内区间
当前US$22.40
52周区间
当前US$22.40
盘中时间采用ET。市场数据可能有所延迟。
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
日内区间
当前US$22.40
52周区间
当前US$22.40
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2404.9万 USD | 1596.5万 USD | 1519.7万 USD | 941.2万 USD | 884.9万 USD |
| 销货成本 | 1334.3万 USD | 840.6万 USD | 917.9万 USD | 690.2万 USD | 645.7万 USD |
| 毛利 | 1070.6万 USD | 755.9万 USD | 601.8万 USD | 251万 USD | 239.2万 USD |
| 研究与开发 | — | 230万 USD | 270万 USD | 270万 USD | 230万 USD |
| 销售、一般及管理费用 | — | 1177.5万 USD | 1363.8万 USD | 1530.7万 USD | 1200.5万 USD |
| 营业费用 | 1190.8万 USD | 1177.5万 USD | 1363.8万 USD | 1530.7万 USD | 1200.5万 USD |
| 利息支出 | 7.3万 USD | 7.4万 USD | 1.8万 USD | 1.2万 USD | 2万 USD |
| 折旧和摊销 | 175.2万 USD | 151.3万 USD | 151.7万 USD | 152万 USD | 144.4万 USD |
| 营业利润 | −120.2万 USD | −421.6万 USD | −762万 USD | −1279.7万 USD | −961.3万 USD |
| 净利润 | −36.3万 USD | −429万 USD | −585.3万 USD | −1220.3万 USD | −855万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年9月22日 | 1:20 | — | — |
股票拆分 | 2019年4月29日 | 1:15 | — | — |
股票拆分 | 2017年6月13日 | 1:30 | — | — |
股票拆分 | 2014年1月28日 | 1:12 | — | — |
已生效 2023年9月22日
1:20
已生效 2019年4月29日
1:15
已生效 2017年6月13日
1:30
已生效 2014年1月28日
1:12
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI96.59万0.00%2.3万亿 USD0.03%US$381.07-0.13%
Vanguard Extended Market ETFVXF49万0.00%954亿 USD0.05%US$232.08-0.62%
iShares Micro-Cap ETFIWC11.54万0.01%13.17亿 USD0.60%US$179.93-0.95%
U.S. Micro Cap Portfolio ETFDFMC6.05万0.00%75.44亿 USD0.43%US$57.49-0.36%
Dimensional - US Small Cap ETFDFAS4.12万0.00%338.04亿 USD0.31%US$78.12-0.06%
Dimensional - US Sustainability Core 1 ETFDFSU2.28万0.00%23.92亿 USD0.15%US$48.115-0.03%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.68万0.00%455.76亿 USD0.17%US$84.39-0.05%
Dimensional - US Core Equity 2 ETFDFAC1.34万0.00%885.59亿 USD0.21%US$45.305-0.01%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
